Stage IIIC Breast Cancer AJCC v7
37
1
15
17
Key Insights
Highlights
Success Rate
85% trial completion
Published Results
19 trials with published results (51%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
8.1%
3 terminated out of 37 trials
85.0%
-1.5% vs benchmark
14%
5 trials in Phase 3/4
112%
19 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 17 completed trials
Clinical Trials (37)
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment
Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer
Neratinib and Paclitaxel With or Without Pertuzumab and Trastuzumab Before Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Breast Cancer
Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
The Role of Lifestyle Factors in Breast Cancer-Related Outcomes
Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib